(Q33214797)

24 July 2017

1 reference

title

Nonsteroidal anti-inflammatory drugs and hepatic toxicity: a systematic review of randomized controlled trials in arthritis patients (English)

1 reference

24 July 2017

1 reference

Alaa Rostom

1

1 reference

24 July 2017

Lawrence Goldkind

series ordinal

2

1 reference

24 July 2017

Loren Laine

series ordinal

3

1 reference

24 July 2017

language of work or name

English

0 references

publication date

1 May 2005

1 reference

Clinical Gastroenterology and Hepatology

24 July 2017

published in

1 reference

24 July 2017

volume

3

1 reference

24 July 2017

issue

5

1 reference

24 July 2017

page(s)

489-498

1 reference

Developing optimal search strategies for detecting clinically sound studies in MEDLINE.

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Locating and appraising systematic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparing the efficacy of cyclooxygenase 2–specific inhibitors in treating osteoarthritis: Appropriate trial design considerations and results of a randomized, placebo‐controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis. Results of two randomized treatment trials of six weeks duration

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of the efficacy and safety of naproxen CR and nabumetone in the treatment of patients with osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A randomized, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Treatment of elderly patients with nabumetone or diclofenac: gastrointestinal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Celecoxib versus diclofenac in the management of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protoco

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of the upper gastrointestinal safety of Arthrotec 75 and nabumetone in osteoarthritis patients at high risk for developing nonsteroidal anti-inflammatory drug-induced gastrointestinal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A double-masked comparison of Naprelan and nabumetone in osteoarthritis of the knee. Naprelan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Meloxicam in osteoarthritis: a 6-month, double-blind comparison with diclofenac sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A comparative study of tenidap, a cytokine-modulating anti-rheumatic drug, and diclofenac in rheumatoid arthritis: a 24-week analysis of a 1-year clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A two-year, placebo-controlled trial of non-steroidal anti-inflammatory therapy in osteoarthritis of the knee joint

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Controlled-release naproxen compared with isoxicam in patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Hepatic and renal tolerability of long-term naproxen treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Six-month multi-center study comparing nabumetone with naproxen in the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A double-blind multicentre trial of piroxicam and naproxen in osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A Multicentre Comparison of Flurbiprofen and Naproxen in Rheumatoid Arthritis: A Four-Week Study in 118 Patients

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Treatment of Rheumatoid Arthritis with Flurbiprofen or Ibuprofen

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Response of osteoarthritis to ibuprofen or flurbiprofen

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Arthrotec: the evidence speaks for itself.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Meloxicam (Mobic): a review of its pharmacological and clinical profile

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

1 reference

7 January 2021

The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Are patients with elevated liver tests at increased risk of drug-induced liver injury?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900777-3

7 January 2021

10.1016/S1542-3565(04)00777-3

Identifiers

DOI

1 reference

release_m7hxnv5karbdlf6j3hfcslrq54

24 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/m7hxnv5karbdlf6j3hfcslrq54

24 November 2022

mapped directly with Wikidata item

1 reference